Salvinorin A: Compound Guide

Safety note. Salvinorin A can cause sudden, intense changes in perception and awareness. NIDA links psychedelic and dissociative drugs to dangerous behavior and injuries, particularly when judgment and perception are impaired. [1] If someone is very confused, extremely agitated, having a seizure or cannot be roused after using any salvia product, call 911 (US) or US Poison Help at 1-800-222-1222. See plant and mushroom poisoning. This page gives no amounts, preparation or use instructions, and does not help identify plants.

Evidence labels used here: promising but limited, insufficient evidence, preclinical (cells or animals only). Where we looked and found nothing usable, we write "Proper evidence not found."

Compound versus plant

Salvinorin A is a single chemical. Salvia divinorum (Lamiaceae, accepted name checked in GBIF) is the sage-family plant it comes from. [2] A pharmacology review says the Mazatec culture has used the plant for centuries, and that its potent effects in case reports led researchers to discover salvinorin A as the first highly selective non-nitrogenous kappa opioid receptor agonist. [3] "Non-nitrogenous" means the molecule has no nitrogen atom, which sets it apart from other known opioid ligands. [4] Leaf preparations and the isolated compound are not the same thing, and a traditional context is not the same as laboratory research. See Salvia divinorum traditional contexts and the plant profile, Salvia divinorum.

How it works, and why it is not a classic psychedelic

NIDA says classic psychedelics such as psilocybin and LSD mainly act on serotonin 5-HT2A receptors. Salvia works differently: it activates kappa opioid receptors. [1] Salvinorin A is a selective, high-efficacy agonist at this receptor, which normally works with the brain's dynorphin system; activating it can cause aversion and a loss of pleasure in preclinical models. [4] Do not assume it acts like psilocybin, LSD or DMT, and do not treat it as an opioid painkiller. See what classic psychedelics are.

Regulatory status (not legal advice; laws change)

• United States, federal: we did not find Salvia divinorum or salvinorin A named in the Schedule I list (21 CFR 1308.11) or the Schedule III list (21 CFR 1308.13) as read on 2026-10-22. [5][6] US state rules, the UK, the EU, Mexico and other countries: not verified.
• Approved medicine: we found no regulator approval of salvinorin A or salvia in the sources we read.

See legal status by country.

What research shows

• Healthy volunteers, laboratory studies: promising but limited as pharmacology, not as treatment.
• A double-blind, placebo-controlled study in 4 hallucinogen-experienced adults, using inhaled salvinorin A in supportive conditions, found effects peaked within minutes and were no longer clearly present at about 20 minutes. Ratings resembled those for classic hallucinogens and included mystical-type items; heart rate and blood pressure did not rise significantly. [7]
• A double-blind crossover study in 10 healthy previous salvia users reported psychotomimetic, dissociative and perceptual effects, raised cortisol and prolactin, no euphoria, no cognitive deficits and no vital-sign changes. Effects were transient and the study reported no acute or delayed adverse effects. [8]
• A randomized crossover study measuring brain activity and blood flow described dramatic psychotomimetic effects with a dissociative character and no dysphoria. [9]
• Limits: very small samples, healthy experienced users, controlled settings. They show what the compound does for minutes, not what happens with repeated use, in other people or outside a lab.
• Therapeutic use: preclinical. The 2007 review says animal studies suggest potential, with many further investigations needed. [3] Reviews describe efforts to develop modified versions of the molecule as possible medicines. [4] Proper evidence not found for a human treatment trial of salvinorin A or salvia leaf.

Risks

• Mental health and thinking. A review of use and misuse says salvia became popular with adolescents and young adults, is widely believed to have low addictive potential and toxicity, but that recent findings suggest salvinorin A can precipitate psychiatric symptoms and affect cognition. Short- and long-term effects have not been examined in enough detail. [10] Label: insufficient evidence of safety.
• Use in young people. In NIDA's report of the 2022 Monitoring the Future survey, 0.8% of 8th, 10th and 12th graders said they used salvia in the past year. [1]
• Medicines and health conditions. Proper evidence not found on interactions with medicines, pregnancy, children or older adults in the sources we read. See medication interactions and talk with a clinician.
• Quality. We found no regulator-published testing of salvia products, so strength and purity claims are a marketing claim.